FDA reviews potential accelerated pathways for approval for Compass Pathways.
4 reports, 4 independent
Updated Sep 24
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA reviews potential accelerated pathways for approval for Compass Pathways.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Compass Pathways NDA submitted to FDA; launch hinges on DEA rescheduling.1 source
FDA reviewed potential accelerated pathways for Compass Pathways on August 1, 2025.1 source
Keep exploring
The entities involved
- FDA
-
Compass Pathways
mental health care company
Related events
- FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
- Donald Trump instructed the FDA to accelerate the drug review process.
- FDA approval expands patient access to therapies for ACCORD.
- Research advances have led to the approval of new therapies by the FDA.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
Coverage
Newest first; wire copies grouped- dailypolitical.com
- yahoo.com
- medicaldaily.com
- GuruFocus.comCompass Pathways PLC (CMPS) Q2 2025 Earnings Call Highlights: Clinical Success and Strategic ... Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full